Effect of aminoguanidine on optic nerve involvement in experimental diabetic rats

Brain Res. 1998 Aug 3;800(2):319-22. doi: 10.1016/s0006-8993(98)00512-5.


The effect of aminoguanidine (AG) on structural abnormalities in optic nerve fibers was evaluated in streptozotocin-induced diabetic rats. Morphometry of myelinated optic nerve fibers showed a partial amelioration on the reduction of the axon size but complete preservation of myelin size with low dose (25 mg kg-1 body weight) AG treatment. High dose (100 mg kg-1 body weight) AG completely prevented myelinated nerve fiber atrophy. These findings indicated that nonenzymatic glycation contributes to the development of optic nerve changes in diabetic rats.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Body Weight
  • Diabetes Mellitus, Experimental / complications*
  • Diabetic Neuropathies / drug therapy*
  • Diabetic Neuropathies / enzymology
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology*
  • Glycation End Products, Advanced / antagonists & inhibitors
  • Glycation End Products, Advanced / metabolism
  • Guanidines / pharmacology*
  • Male
  • Nerve Fibers, Myelinated / drug effects
  • Nerve Fibers, Myelinated / metabolism
  • Optic Nerve Diseases / drug therapy*
  • Optic Nerve Diseases / enzymology
  • Rats
  • Rats, Wistar


  • Enzyme Inhibitors
  • Glycation End Products, Advanced
  • Guanidines
  • pimagedine